A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease

Timeline

Start

2021-08-04

Primary completion

2022-09-02

Completion

2023-08-02

Outcome

Outcome not reported

Stopped (Business): “This decision is made on changing the development strategy of GT0918 to adapt ever-changing COVID-19 pandemic management globally.”

Drugs

Indications